Targeting surface protein SasX by active and passive vaccination to reduce Staphylococcus aureus colonization and infection

Infection and Immunity
Qian LiuMin Li

Abstract

SasX is a recently described surface protein of Staphylococcus aureus that is linked to the epidemic success of hospital-associated methicillin-resistant clones, in particular in Asia. It enhances nasal colonization and virulence in skin and lung infection models. Here, we evaluated the potential of SasX as a vaccine component in passive and active immunization efforts using mouse infection models. We found that SasX induced a specific immune response predominantly based on IgG1 antibodies. Active immunization with recombinant SasX or passive immunization with rabbit polyclonal anti-SasX IgG significantly decreased the size of lesions caused by S. aureus in a skin infection model. Furthermore, active immunization reduced acute lung injury in a lung infection model. Moreover, active or passive immunization significantly reduced S. aureus colonization in a nasal colonization model. Finally, anti-SasX IgG enhanced the susceptibility of S. aureus to killing by human neutrophils. We conclude that SasX is a potential target for therapeutics or vaccines designed to moderate colonization and infection by sasX-positive epidemic strains of S. aureus.

References

Aug 26, 1998·The New England Journal of Medicine·F D Lowy
Jan 4, 2001·The New England Journal of Medicine·C von EiffG Peters
Oct 1, 1995·American Journal of Therapeutics·Ravi MalaviyaSoman N. Abraham
May 2, 2002·Proceedings of the National Academy of Sciences of the United States of America·Scott D KobayashiFrank R DeLeo
Jun 19, 2004·The International Journal of Biochemistry & Cell Biology·M Maurer, E von Stebut
Oct 26, 2005·Trends in Microbiology·Suzan H M RooijakkersJos A G van Strijp
Nov 29, 2005·The Lancet Infectious Diseases·Heiman F L WertheimJan L Nouwen
Jan 18, 2008·PLoS Medicine·Heiman F L WertheimAlex van Belkum
Feb 13, 2008·The Journal of Experimental Medicine·Frank R DeLeo, Michael Otto
Jan 13, 2009·Infectious Disease Clinics of North America·Adam C Schaffer, Jean C Lee
Sep 5, 2009·The Journal of Clinical Investigation·Frank R DeLeo, Henry F Chambers
Jun 10, 2010·Expert Opinion on Biological Therapy·Michael Otto
Nov 15, 2011·Seminars in Immunopathology·Kevin M Rigby, Frank R DeLeo
Mar 4, 2014·Current Opinion in Microbiology·Michael Otto

❮ Previous
Next ❯

Citations

Oct 22, 2016·Trends in Microbiology·Michelle E Mulcahy, Rachel M McLoughlin
Sep 25, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Richard A Proctor
May 27, 2016·Microbiology Spectrum·Alexandra E Paharik, Alexander R Horswill
May 21, 2021·MSphere·Mariane PivardFrançois Vandenesch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.